Amid hundreds of emails, phone calls and messages, Tim Ezell opens up about his absence from FOX 2 News in the morning and ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of "Power in the Periphery," a new disease education ...

Shy Drager syndrome was the name for the condition now known as multiple system atrophy (MSA), a neurological condition first recognized in the 1960s. It was traditionally diagnosed when someone began ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...

α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...

"Multiple System Atrophy Clinical Trials Analysis"DelveInsight's,“Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...